Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xuebijing for sepsis prognosis assessed by whole-blood thrombotic biomarkers
ChiCTR2600133619Phase 4Not yet recruiting
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
- Start
- Dec 2025
- Countries
- 1
01
Overview
Phase 4, open-label trial of xuebijing in sepsis (2 arms), sponsored by Guangdong Provincial Hospital of Traditional Chinese Medicine. Primary endpoints: Thrombotic molecular biomarkers, Disease severity association and 2 more. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
xuebijing
03
Conditions
sepsis
Beyond the preview
Go deeper on ChiCTR2600133619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133619.